ATRION Co. (NASDAQ:ATRI) has received a consensus broker rating score of 5.00 (Strong Sell) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong sell rating.
Brokers have set a 12 month consensus price target of $300.00 for the company, according to Zacks. Zacks has also assigned ATRION an industry rank of 191 out of 265 based on the ratings given to its competitors.
Separately, BidaskClub raised shares of ATRION from a “strong sell” rating to a “sell” rating in a report on Thursday, March 29th.
Hedge funds have recently added to or reduced their stakes in the company. Citadel Advisors LLC purchased a new stake in shares of ATRION in the 4th quarter valued at $269,000. Stone Ridge Asset Management LLC acquired a new position in shares of ATRION in the 4th quarter valued at $271,000. Teacher Retirement System of Texas acquired a new position in shares of ATRION in the 4th quarter valued at $323,000. Bank of Montreal Can lifted its stake in shares of ATRION by 25.7% in the 4th quarter. Bank of Montreal Can now owns 597 shares of the medical instruments supplier’s stock valued at $376,000 after purchasing an additional 122 shares during the period. Finally, MetLife Investment Advisors LLC acquired a new position in shares of ATRION in the 4th quarter valued at $390,000. 59.07% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ:ATRI traded down $4.57 during trading hours on Thursday, hitting $602.08. 4,164 shares of the company were exchanged, compared to its average volume of 7,865. The company has a market cap of $1,124.44, a PE ratio of 32.84 and a beta of 0.67. ATRION has a 52-week low of $477.40 and a 52-week high of $694.00.
ATRION (NASDAQ:ATRI) last released its earnings results on Tuesday, February 27th. The medical instruments supplier reported $4.66 earnings per share for the quarter. The company had revenue of $34.02 million for the quarter. ATRION had a net margin of 24.96% and a return on equity of 19.53%.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 30th. Stockholders of record on Thursday, March 15th were issued a $1.20 dividend. This represents a $4.80 annualized dividend and a dividend yield of 0.80%. The ex-dividend date of this dividend was Wednesday, March 14th.
TRADEMARK VIOLATION NOTICE: This story was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.thelincolnianonline.com/2018/04/17/zacks-atrion-co-atri-given-300-00-consensus-price-target-by-brokerages.html.
ATRION Company Profile
Atrion Corp. engages in the manufacture and development of products for medical applications. It involves in the marketing of components to other equipment manufacturers for incorporation in their products and sell finished devices to physicians, hospitals, clinics and other treatment centers. It specializes in the fluid delivery, as well as ophthalmic and cardiovascular devices.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ATRION Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ATRION and related companies with MarketBeat.com's FREE daily email newsletter.